CD8⁺ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens

Abstract

These data suggest a complex interplay between CD8⁺ T cells and tumors and define DP Temra as a unique subset of tumor-specific CD8⁺ TILs that are produced in patients with relatively low immunogenic cancer types, predicting immunogenicity of tumor antigens and CD8⁺ TIL counts, a reliable biomarker for successful cancer immunotherapy.